Spruce Biosciences Inc

NASDAQ:SPRB

Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Daly City, California and currently employs 15 full-time employees. The company went IPO on 2020-10-09. The firm is focused on developing and commercializing therapies for rare endocrine disorders. The firm's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a potent and selective, non-steroidal, oral, small-molecule antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is a regulator of the production of adrenocorticotropic hormone (ACTH). Its CAHmelia-203, is a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with CAH with poor disease control. Its CAHmelia-204, is a second Phase IIb clinical trial in adult patients with CAH with good disease control focused on glucocorticoid reduction. The company has also conducted two Phase IIa clinical trials of tildacerfont in adult patients with CAH on stable glucocorticoid therapy.